Pfizer Attacked Over Lipitor Licensing Pact
On Tuesday, Astellas filed suit at the Tokyo District Court, asking the court to weigh in on a dispute over when the duo’s marketing agreement involving Lipitor expires.
The Japanese company currently sells Lipitor under a previously established licensing agreement with Pfizer.
The contract is supposed to be valid until the expiration of the drug's patents, which cover Lipitor's...
To view the full article, register now.